Oskar has a broad biotech and business background and is currently partner at BioGeneration Ventures. Oskar started his career in McKinsey & Company as a management consultant. After that he held positions in Crucell, first in business development and later he became responsible for the Pediatric Franchise. After the acquisition of Crucell by Johnson & Johnson, Oskar led the Vaccines & Infectious Diseases business unit in Johnson & Johnson’s pharma joint venture Xian Janssen in Beijing, China. Prior to joining BioGeneration Oskar was Chief Commercial Officer of Avantium, a leading chemical technology company and a forerunner in renewable chemistry.
Oskar has a degree in chemical engineering from Twente University and holds a MBA from INSEAD.
Oskar serves on several boards of companies in BioGeneration’s portfolio.
René studied Business Economics in Amsterdam. Focussing on Finance and Management. He is an experienced private equity and venture capital investor.
For many years he was director at NPM Capital, one of the largest family held investment companies in Holland and partner at Berk partners, a hands-on private equity fund. He was actively involved with a large number of investments, exits, trade sales and three IPO’s.
René focusses mainly on Life Science investments and technology orientated companies. As a senior investment manager at InnovationQuarter he is responsible for the life Science investments in the region of South Holland. InnovationQuarter, instructed by the Government, focusses on investments in fast growing innovative companies.
He combines his investment expertise and experience with his network to support the portfolio companies in their growth.
Edward van WezelMember
Edward is the founder and managing partner at BioGeneration Ventures. Edward currently serves on the supervisory boards of 7 biotech companies. Edward started his career as process engineer for Chiron Inc.. He subsequently worked in product development and corporate licensing at Johnson & Johnson. Since 2000 he expanded his experience as CEO of several life sciences companies in the Netherlands. Edward holds a M.Sc. in chemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the Delft University of Technology.
Senior Executive with international experience in Biotechnology and Pharma. Management appointments in Large and Mid-Cap US/EU Biopharma companies (Novo Nordisk, ZymoGenetics inc). Proven track record with product approvals, financing, M&A and IPO at Nasdaq (ZGEN) and Euronext (BUP.PA). Incorporated ProFibrix Inc in 2008, and as CEO in 2013 led ProFibrix through $240Mill M&A with The Medicines Company after successful Phase 3 completion and approvals in EU and US. Chairman of the Board at Biomup SA, GTXmedical BV and Blaze Biosciences Inc. M.D from Univ of Copenhagen followed by six years surgical training. Dr Öhrström is a Danish citizen and resident in the Netherlands.